伏立诺他
组蛋白脱乙酰基酶
表观遗传学
癌症
医学
临床试验
药理学
组蛋白
癌细胞
癌症研究
生物信息学
生物
内科学
遗传学
基因
作者
Hyun-Jung Kim,Suk‐Chul Bae
出处
期刊:PubMed
日期:2011-02-01
被引量:216
摘要
Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells. Recently, their use has been clinically validated in cancer patients resulting in the approval of two HDAC inhibitors, vorinostat and depsipetide, by the FDA. Also, clinical trials of several HDAC inhibitors for use as anti-cancer drugs (alone or in combination with other anti-cancer therapeutics) are ongoing. However, the molecular mechanisms underlying the response to HDAC inhibitors in cancer patients are not fully understood. In this review, we summarize our understanding of the molecular and biological events that underpin the anticancer effects of HDAC inhibitors and the outcomes of recent clinical trials involving these drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI